File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong

TitleEvaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong
Authors
KeywordsPCV13
PPSV23
pneumonia
cost-effectiveness
pharmacoeconomics
Issue Date2020
PublisherTaylor & Francis Inc. The Journal's web site is located at http://www.tandfonline.com/khvi
Citation
Human Vaccines & Immunotherapeutics, 2020, v. 16 n. 8, p. 1937-1944 How to Cite?
AbstractTwo vaccines, 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13), are widely available for the prevention of pneumococcal disease in adults. However, it is unclear how cost-effective these pneumococcal vaccine choices are in the Hong Kong healthcare environment. We aimed to assess the cost-effectiveness of a sequential administration of PCV13 followed by PPSV23 compared to a single dose of PPSV23 vaccination for pneumococcal disease control in Hong Kong adults aged ≥65 years and individuals aged 20–64 years with immunocompromising and chronic conditions. A previously developed deterministic cohort sequential model was applied to compare the outcomes of two vaccination strategies from a societal perspective. Population-specific model input, including incidence, mortality, case-fatality, risk group distribution, vaccination costs, disease management, and productivity loss, was estimated from a Hong Kong-wide electronic medical database. Costs were valued in US$ in 2017. Vaccination strategies with an incremental cost-effectiveness ratio (ICER, defined as incremental cost per QALY saved) less than one local GDP per capita ($46,193 in 2017) were defined as highly cost-effective. Deterministic sensitivity analyses (SA) were conducted. Compared with single-dose PPSV23, sequential vaccination of PCV13 followed by PPSV23 was cost-saving for adults aged ≥20 years. In the deterministic SA, the base-case results were robust for tested parameter uncertainties. Future vaccination policies should consider the cost-effectiveness of a sequential vaccination strategy as a measure to reduce the vaccine-preventable pneumococcal disease burden in Hong Kong.
Persistent Identifierhttp://hdl.handle.net/10722/284680
ISSN
2019 Impact Factor: 2.619
2015 SCImago Journal Rankings: 0.935

 

DC FieldValueLanguage
dc.contributor.authorSHAMI, JJP-
dc.contributor.authorPathadka, S-
dc.contributor.authorChan, EW-
dc.contributor.authorHui, J-
dc.contributor.authorSato, R-
dc.contributor.authorPatil, S-
dc.contributor.authorLi, X-
dc.date.accessioned2020-08-07T09:01:09Z-
dc.date.available2020-08-07T09:01:09Z-
dc.date.issued2020-
dc.identifier.citationHuman Vaccines & Immunotherapeutics, 2020, v. 16 n. 8, p. 1937-1944-
dc.identifier.issn2164-5515-
dc.identifier.urihttp://hdl.handle.net/10722/284680-
dc.description.abstractTwo vaccines, 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13), are widely available for the prevention of pneumococcal disease in adults. However, it is unclear how cost-effective these pneumococcal vaccine choices are in the Hong Kong healthcare environment. We aimed to assess the cost-effectiveness of a sequential administration of PCV13 followed by PPSV23 compared to a single dose of PPSV23 vaccination for pneumococcal disease control in Hong Kong adults aged ≥65 years and individuals aged 20–64 years with immunocompromising and chronic conditions. A previously developed deterministic cohort sequential model was applied to compare the outcomes of two vaccination strategies from a societal perspective. Population-specific model input, including incidence, mortality, case-fatality, risk group distribution, vaccination costs, disease management, and productivity loss, was estimated from a Hong Kong-wide electronic medical database. Costs were valued in US$ in 2017. Vaccination strategies with an incremental cost-effectiveness ratio (ICER, defined as incremental cost per QALY saved) less than one local GDP per capita ($46,193 in 2017) were defined as highly cost-effective. Deterministic sensitivity analyses (SA) were conducted. Compared with single-dose PPSV23, sequential vaccination of PCV13 followed by PPSV23 was cost-saving for adults aged ≥20 years. In the deterministic SA, the base-case results were robust for tested parameter uncertainties. Future vaccination policies should consider the cost-effectiveness of a sequential vaccination strategy as a measure to reduce the vaccine-preventable pneumococcal disease burden in Hong Kong.-
dc.languageeng-
dc.publisherTaylor & Francis Inc. The Journal's web site is located at http://www.tandfonline.com/khvi-
dc.relation.ispartofHuman Vaccines & Immunotherapeutics-
dc.subjectPCV13-
dc.subjectPPSV23-
dc.subjectpneumonia-
dc.subjectcost-effectiveness-
dc.subjectpharmacoeconomics-
dc.titleEvaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong-
dc.typeArticle-
dc.identifier.emailPathadka, S: swathip@hku.hk-
dc.identifier.emailChan, EW: ewchan@hku.hk-
dc.identifier.emailLi, X: sxueli@hku.hk-
dc.identifier.authorityChan, EW=rp01587-
dc.identifier.authorityLi, X=rp02531-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/21645515.2019.1711300-
dc.identifier.pmid31977268-
dc.identifier.scopuseid_2-s2.0-85078498116-
dc.identifier.hkuros311615-
dc.identifier.volume16-
dc.identifier.issue8-
dc.identifier.spage1937-
dc.identifier.epage1944-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats